When Should Transient Elastography Be Ordered?

Answer in brief: Transient elastography should be ordered when a patient has suspected chronic liver disease and fibrosis stage will affect management, especially after an indeterminate or elevated FIB-4, in patients with MASLD and metabolic risk, chronic viral hepatitis, alcohol-associated liver disease, or when cirrhosis/portal hypertension is suspected. It is most useful as a second-step noninvasive fibrosis test rather than a universal screening test.

Key clinical points

Use VCTE after FIB-4 identifies intermediate or high fibrosis risk.
Interpret stiffness in the context of etiology and clinical state.
Inflammation, congestion and cholestasis can falsely increase stiffness.
Liver stiffness also helps stratify portal-hypertension risk in compensated cirrhosis.

Role in MASLD

AASLD recommends a two-step approach: first a simple blood-based score such as FIB-4, then VCTE or ELF when FIB-4 is elevated or indeterminate. In MASLD, VCTE liver stiffness <8 kPa is often reassuring against advanced fibrosis, whereas higher values require increasingly careful evaluation.

Beyond MASLD

Elastography is useful in chronic hepatitis B or C, alcohol-associated liver disease and other chronic liver conditions, although disease-specific cutoffs differ. A single kPa value should therefore not be interpreted without knowing the underlying disease and test quality.

False elevation

Acute hepatitis, recent heavy alcohol exposure with inflammation, hepatic congestion, biliary obstruction and sometimes postprandial state can increase stiffness independent of fibrosis. Testing should ideally occur under standardized conditions when the patient is clinically stable.

Portal hypertension

In established or suspected compensated cirrhosis, liver stiffness combined with platelet count can help identify clinically significant portal hypertension and determine whether EGD screening can be deferred or whether nonselective beta-blocker therapy should be considered.

Practical approach

1. Define the liver-disease phenotype and metabolic/alcohol/medication context.

2. Use FIB-4 as first-line fibrosis triage when appropriate.

3. Escalate to VCTE/ELF or other testing when risk is indeterminate or high.

4. Refer or biopsy when noninvasive tests conflict, advanced disease is likely or diagnosis remains uncertain.

Common errors to avoid

Treating FIB-4 or elastography as a stand-alone diagnosis.
Interpreting noninvasive fibrosis tests during acute illness without context.

Trainee takeaway

Transient elastography should be ordered when a patient has suspected chronic liver disease and fibrosis stage will affect management, especially after an indeterminate or elevated FIB-4, in patients with MASLD and metabolic risk, chronic viral hepatitis, alcohol-associated liver disease, or when cirrhosis/portal hypertension is suspected. The examination question is usually less about memorizing one cutoff than recognizing which finding changes the next clinical decision.

Relevant free books by Dr. Alan B. R. Thomson

Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015. ISBN 978-1502928078.
Thomson ABR. Endoscopy and Diagnostic Imaging, Parts I–II. CAPstone Academic Publishers; 2012.

Free downloads: https://giandhepatology.com/free-medical-books-on-gastroenterology-and-hepatology

Frequently asked questions

Is FibroScan the same as transient elastography?

FibroScan is a widely used device that performs vibration-controlled transient elastography.

Does an elevated stiffness measurement prove cirrhosis?

No. It increases the probability of advanced fibrosis or cirrhosis but must be interpreted with disease-specific thresholds and clinical context.

References

1. Thomson ABR. Guideline-Based Management in Hepatology. CAPstone Academic Publishers; 2015. ISBN 978-1502928078.

2. Thomson ABR. Endoscopy and Diagnostic Imaging, Parts I–II. CAPstone Academic Publishers; 2012.

3. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-1835. doi:10.1097/HEP.0000000000000323.

4. Kaplan DE, Ripoll C, Thiele M, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology. 2024;79:1180-1211. doi:10.1097/HEP.0000000000000647.

Editorial note: This educational article synthesizes Dr. Thomson’s teaching framework with current society guidance. Recommendations should be checked against the latest guideline, local formulary, regulatory labeling and the individual clinical context before patient-specific use.